Penumbra (PEN) Overweight Rating Kept at JP Morgan; The Target Price is $200.0000; Isramco (ISRL)’s Sentiment Is 0.92

Penumbra, Inc. (NYSE:PEN) Logo

Isramco Inc (ISRL) investors sentiment decreased to 0.92 in Q2 2019. It’s down -1.51, from 2.43 in 2019Q1. The ratio has worsened, as 17 active investment managers increased and opened new holdings, while 7 sold and trimmed equity positions in Isramco Inc. The active investment managers in our database now possess: 133,201 shares, up from 130,397 shares in 2019Q1. Also, the number of active investment managers holding Isramco Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 7 Increased: 11 New Position: 6.

In a research note issued to investors and clients on today, JP Morgan maintained their Overweight rating on Penumbra (NYSE:PEN)‘s stock. The target price means a potential upside of 15.25% from company’s last stock close.

The stock increased 1.46% or $2.5 during the last trading session, reaching $173.53. About 229,937 shares traded. Penumbra, Inc. (NYSE:PEN) has risen 20.32% since December 4, 2018 and is uptrending. It has outperformed by 20.32% the S&P500. Some Historical PEN News: 23/04/2018 – penumbra, inc. | penumbra coil 400, ruby coil system, pod | K173614 | 04/17/2018 |; 08/05/2018 – PENUMBRA INC PEN.N FY2018 REV VIEW $406.1 MLN — THOMSON REUTERS l/B/E/S; 03/05/2018 – Penumbra Presenting at Bank of America Conference May 17; 08/05/2018 – Penumbra 1Q EPS 15c; 08/05/2018 – PENUMBRA INC – QTRLY SHR $0.15; 09/05/2018 – PENUMBRA INC PEN.N : BMO RAISES TO $140 FROM $115; 08/05/2018 – PENUMBRA 1Q REV. $102.7M, EST. $91.8M; 19/04/2018 – DJ Penumbra Inc, Inst Holders, 1Q 2018 (PEN); 08/05/2018 – PENUMBRA SEES FY REV. $410M TO $415M, EST. $406.1M; 30/05/2018 – Penumbra at Goldman Sachs Global Health Care Conference Jun 12

Analysts await Penumbra, Inc. (NYSE:PEN) to report earnings on February, 25. They expect $0.18 EPS, up 38.46% or $0.05 from last year’s $0.13 per share. PEN’s profit will be $6.28M for 241.01 P/E if the $0.18 EPS becomes a reality. After $0.25 actual EPS reported by Penumbra, Inc. for the previous quarter, Wall Street now forecasts -28.00% negative EPS growth.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $6.06 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It has a 144.37 P/E ratio. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

More notable recent Penumbra, Inc. (NYSE:PEN) news were published by: which released: “Introducing Penumbra (NYSE:PEN), The Stock That Zoomed 151% In The Last Three Years – Yahoo Finance” on November 19, 2019, also with their article: “10 Biggest Price Target Changes For Wednesday – Benzinga” published on December 04, 2019, published: “Penumbra Inc (PEN) Q3 2019 Earnings Call Transcript – Motley Fool” on November 08, 2019. More interesting news about Penumbra, Inc. (NYSE:PEN) were released by: and their article: “Penumbra appoints new CFO – Seeking Alpha” published on November 26, 2019 as well as‘s news article titled: “Maggie Yuen Appointed Chief Financial Officer Of Penumbra – PRNewswire” with publication date: November 25, 2019.

More notable recent Isramco, Inc. (NASDAQ:ISRL) news were published by: which released: “Tourism in Israel? U.S. charity’s offer with Gaza hospital project irks Palestinians – Nasdaq” on December 03, 2019, also with their article: “Israel Finance Minister Kahlon mulling resignation – Globes – Nasdaq” published on December 04, 2019, published: “Israel’s Netanyahu, Pompeo to meet in Lisbon this week -U.S. – Nasdaq” on December 03, 2019. More interesting news about Isramco, Inc. (NASDAQ:ISRL) were released by: and their article: “Israel’s TowerJazz to maintain 51% stake in Panasonic chip JV – Nasdaq” published on December 02, 2019 as well as‘s news article titled: “JP Morgan becomes primary dealer in Israel government bonds – Nasdaq” with publication date: December 03, 2019.

Isramco, Inc., an independent oil and natural gas company, engages in the exploration, development, and production of oil and natural gas properties located onshore in the United States and offshore Israel. The company has market cap of $330.60 million. It operates through two divisions, Oil and Gas Exploration and Production; and Production Services. It has a 22.82 P/E ratio. The Oil and Gas Exploration and Production segment owns working interests in gas and oil wells in Louisiana, Texas, New Mexico, Oklahoma, Wyoming, Utah, and Colorado; and operates approximately 515 producing wells located primarily in Texas and New Mexico.

It closed at $121.65 lastly. It is up 11.77% since December 4, 2018 and is uptrending. It has outperformed by 11.77% the S&P500. Some Historical ISRL News: 21/03/2018 NAPHTHA WEIGHS DELISTING ISRAMCO INC. FROM NASDAQ; 09/05/2018 – Isramco Short-Interest Ratio Rises 128% to 48 Days; 22/04/2018 – DJ Isramco Inc, Inst Holders, 1Q 2018 (ISRL)

Alliancebernstein L.P. holds 0% of its portfolio in Isramco, Inc. for 1,721 shares. American International Group Inc owns 470 shares or 0% of their US portfolio. Moreover, Ameritas Investment Partners Inc. has 0% invested in the company for 85 shares. The California-based Aperio Group Llc has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 608 shares.

Isramco, Inc. (NASDAQ:ISRL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.